Adlai Nortye (ANL) Debt Ratio (2022 - 2025)

Adlai Nortye (ANL) reported Debt Ratio of 0.71 for Q4 2025, up 93.24% year-over-year from 0.37 in Q4 2024, and up 16.75% on a QoQ basis from 0.61 in Q2 2025.

Adlai Nortye (ANL) has 4 years of Debt Ratio data on file, last reported at 0.71 in Q4 2025.

  • Quarterly Debt Ratio rose 93.24% year-over-year to 0.71 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.71 (up 93.24% YoY) and the FY2025 annual result came in at 0.71, up 93.24% from the prior year.
  • Debt Ratio climbed to 0.71 in Q4 2025 per ANL's latest filing, from 0.61 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.71 in Q4 2025 and bottomed at 0.06 in Q4 2022.
  • The 4-year median for Debt Ratio is 0.37 (2024), against an average of 0.39.
  • The widest annual swing landed in 2023, when Debt Ratio jumped 293.02%; it then jumped 58.44% in 2024.
  • Tracing ANL's Debt Ratio over 4 years: stood at 0.06 in 2022, then jumped by 293.02% to 0.23 in 2023, then jumped by 58.44% to 0.37 in 2024, then soared by 93.24% to 0.71 in 2025.
  • Per Business Quant, the three latest ANL Debt Ratio figures stand at 0.71 (Q4 2025), 0.61 (Q2 2025), and 0.37 (Q4 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn 0.18
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - 1.41
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 0.05
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn -
10 Adlai Nortye 23,840.00 -8.03 Mn - 0.71

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 0.71
Jun 30, 2025 0.61
Dec 31, 2024 0.37
Jun 30, 2024 0.36
Dec 31, 2023 0.23
Dec 31, 2022 0.06